Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study

被引：5
|
作者：
Soto, Caitlin L. [1 ]
Hsu, Alice J. [1 ]
Lee, Jae Hyoung [2 ]
Dzintars, Kathryn [1 ]
Choudhury, Rebecca [3 ]
Jenkins, Timothy C. [4 ]
Mccreary, Erin K. [5 ]
Quartuccio, Katelyn S. [6 ]
Stohs, Erica J. [7 ]
Zimmerman, Matty [1 ]
Tamma, Pranita D. [2 ,8 ]
机构：
[1] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD USA
[2] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21287 USA
[3] Montefiore Med Ctr, Dept Med, Bronx, NY USA
[4] Denver Hlth, Dept Med, Denver, CO USA
[5] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA USA
[6] Univ Rochester, Med Ctr, Dept Pharm, Rochester, NY 14627 USA
[7] Univ Nebraska, Dept Med, Med Ctr, Omaha, NE USA
[8] Johns Hopkins Univ, Dept Pediat, Sch Med, 200 North Wolfe St,Rubinstein Bldg,Rm 3149, Baltimore, MD 21287 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 01期
关键词：
carbapenem-resistant Enterobacterales; bacteremia; ceftazidime-avibactam; meropenem-vaborbactam;
D O I：
10.1093/cid/ciad476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).
引用
收藏
页码：27 / 30
页数：4
相关论文
共 50 条
  • [41] Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
    Oliva, Alessandra
    Liguori, L.
    Covino, S.
    Petrucci, F.
    Cogliati-Dezza, F.
    Curtolo, A.
    Savelloni, G.
    Comi, M.
    Sacco, F.
    Ceccarelli, G.
    Viscido, A.
    Alessandri, F.
    Raponi, G.
    Pugliese, F.
    Mastroianni, C. M.
    Venditti, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (06) : 1149 - 1160
  • [42] Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections
    Debnath, Ashita
    Pillinger, Kelly E.
    Martin, Alysa J.
    Dobrzynski, David
    Cameron, Andrew
    Shulder, Stephanie
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (07) : 803 - 812
  • [43] Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan
    Chin-Fang Su
    Chien Chuang
    Yi-Tsung Lin
    Yu-Jiun Chan
    Jung-Chung Lin
    Po-Liang Lu
    Ching-Tai Huang
    Jann-Tay Wang
    Yin-Ching Chuang
    L. Kristopher Siu
    Chang-Phone Fung
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 651 - 659
  • [44] Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis
    Chen, Yan
    Huang, Hui-Bin
    Peng, Jin-Min
    Weng, Li
    Du, Bin
    MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [45] Efficacy and safety of colistin sulfate in the treatment of infections caused by carbapenem-resistant organisms: a multicenter retrospective cohort study
    Peng, Danyang
    Zhang, Fan
    Chen, Yinyin
    Zhao, Congyi
    Niu, Jingjing
    Yang, Jianxu
    Li, Zhifeng
    Chen, Chao
    Qiu, Shi
    Zhang, Huifeng
    Qin, Bingyu
    Fang, Xiang
    Guo, Suping
    Liu, Ying
    Shao, Huanzhang
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1794 - 1804
  • [46] Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan
    Su, Chin-Fang
    Chuang, Chien
    Lin, Yi-Tsung
    Chan, Yu-Jiun
    Lin, Jung-Chung
    Lu, Po-Liang
    Huang, Ching-Tai
    Wang, Jann-Tay
    Chuang, Yin-Ching
    Siu, L. Kristopher
    Fung, Chang-Phone
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (04) : 651 - 659
  • [47] Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
    Clancy, Cornelius J.
    Potoski, Brian A.
    Buehrle, Deanna
    Nguyen, M. Hong
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (08):
  • [48] Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study
    Iannaccone, Marco
    Boattini, Matteo
    Bianco, Gabriele
    Corcione, Silvia
    Cavallo, Rossana
    Costa, Cristina
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (03) : 160 - 162
  • [49] Case-case-control study of risk factors for carbapenem-resistant Enterobacterales infections among hospitalized patients
    Stuever, David M.
    Ferketich, Amy K.
    Lee, Jiyoung
    Stevenson, Kurt B.
    Wittum, Thomas E.
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2022, 2 (01):
  • [50] Bloodstream infections due to carbapenem-resistant enterobacteriaceae in hematological patients: A retrospective single-center study
    Zhang, L.
    Lin, Q.
    Jiang, E.
    Han, M.
    Wang, J.
    Feng, S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 284 - 285
12345